Kraus, Alan

Kraus, Alan was paid $7K by Medicaid between Feb 2020 and Dec 2020, across 8 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 76% of everything it billed.

33Billing provider infoKRAUS, ALAN
COLLIERVILLE, TN 38017

33aNPI1114918224assigned 10/31/2005

33bProvider typePain Medicine (Anesthesiology) Physician

28Total paid$7K

24GClaims1,774

24DCodes billed8

24AFirst – last monthFeb 2020 – Dec 2020

Compared with peers

Next to other Pain Medicine (Anesthesiology) Physician providers in Tennessee

Rank by total paid#19 of 26

Median peer was paid$38K

This provider vs. median0.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	1,774	$7K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	76%	574	491	$5K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	11%	106	94	$760.74
99442		7.0%	166	152	$473.05
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	6.0%	88	77	$406.75
G8730	Pain assessment documented as positive using a standardized tool and a follow-up plan is documented	0%	232	192	$0.00
G9562	Patients who had a follow-up evaluation conducted at least every three months during opioid therapy	0%	188	151	$0.00
G9584	Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy	0%	200	164	$0.00
G9578	Documentation of signed opioid treatment agreement at least once during opioid therapy	0%	220	181	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.